The Pilot and Feasibility Program (P&F) of the DRTC has funded 127 grants since its inception in 1977. In addition, this past cycle the P&F program funded 6 applications from investigators located outside the University of Chicago, both assisting their diabetes related studies, but also importantly the P&F program acts as a catalyst to bring together researchers from throughout the Chicago area. We plan to expand the program in the coming cycle to also include investigators at the Medical College of Wisconsin. The overall goal of the P&F program is to provide initial support to newly established investigators and also to bring the expertise of more established investigators from other fields into diabetes research. Proposals are sought each year from within the University of Chicago as well as from 6 other Chicago based institutions. All proposals are evaluated by an internal and external reviewer as well as by a member of the P&F Steering Committee. Priority scores and written reviews are then presented to the entire Steering Committee and funding decisions are made. A second year funding is possible for those investigators who have made significant documented progress on their proposed research. All P&F grant recipients are strongly encouraged to present their findings at the Annual Chicago Diabetes Day held at the University of Chicago. The vast majority of P&F grants recipients have remained in diabetes research, and many have received subsequent external funding from the NIH (lllustration VI). Thus, the P&F program is an integral part of promoting diabetes research throughout the greater Chicagoland area and has also greatly enhanced the visibility of the entire DRTC program at the University of Chicago.
The University of Chicago DRTC Pilot and Feasibility Program provides funding to new and established investigators to pursue novel research directions related to the understanding of the causes and complications of diabetes. The P&F Program actively works to bring diabetes researchers together as collaborators from throughout the greater Chicagoland area.
|Smith, Erika; Greeley, Siri Atma W; Ye, Honggang et al. (2016) Extremely Early Onset IPEX Syndrome Caused by a Novel Small Exonic Deletion in FOXP3. J Pediatr Gastroenterol Nutr 63:e119-e120|
|(2016) Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. Nat Genet 48:1151-61|
|Alarcon, Cristina; Boland, Brandon B; Uchizono, Yuji et al. (2016) Pancreatic Î²-Cell Adaptive Plasticity in Obesity Increases Insulin Production but Adversely Affects Secretory Function. Diabetes 65:438-50|
|Sathe, Neha A; Nocon, Robert S; Hughes, Brenna et al. (2016) The Costs of Participating in a Diabetes Quality Improvement Collaborative: Variation Among Five Clinics. Jt Comm J Qual Patient Saf 42:18-25|
|(2016) The genetic architecture of type 2 diabetes. Nature 536:41-7|
|Yi, Yaling; Sun, Xingshen; Gibson-Corley, Katherine et al. (2016) A Transient Metabolic Recovery from Early Life Glucose Intolerance in Cystic Fibrosis Ferrets Occurs During Pancreatic Remodeling. Endocrinology 157:1852-65|
|Hoang, Danh-Tai; Hara, Manami; Jo, Junghyo (2016) Design Principles of Pancreatic Islets: Glucose-Dependent Coordination of Hormone Pulses. PLoS One 11:e0152446|
|Sun, Juan; Mao, Li-Qun; Polonsky, Kenneth S et al. (2016) Pancreatic Î²-Cell Death due to Pdx-1 Deficiency Requires Multi-BH Domain Protein Bax but Not Bak. J Biol Chem 291:13529-34|
|Volden, Paul A; Skor, Maxwell N; Johnson, Marianna B et al. (2016) Mammary Adipose Tissue-Derived Lysophospholipids Promote Estrogen Receptor-Negative Mammary Epithelial Cell Proliferation. Cancer Prev Res (Phila) 9:367-78|
|Horikoshi, Momoko; Pasquali, Lorenzo; Wiltshire, Steven et al. (2016) Transancestral fine-mapping of four type 2 diabetes susceptibility loci highlights potential causal regulatory mechanisms. Hum Mol Genet 25:2070-2081|
Showing the most recent 10 out of 202 publications